NCT04334421 is a clinical trial of Composite mesh in Rectal Cancer, sponsored by Elisa Mäkäräinen.

Who is sponsoring NCT04334421?

NCT04334421 is sponsored by Elisa Mäkäräinen.

What drugs are being tested in NCT04334421?

Interventions in NCT04334421: Composite mesh.

What condition does NCT04334421 study?

NCT04334421 studies Rectal Cancer, Abdominoperineal Resection, Wound Heal.

Is NCT04334421 still recruiting?

NCT04334421 is currently completed. Last updated 1 February 2024.

Last reviewed 2024-02-01 · How we verify

NCT04334421

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APEMESH- Preventing Perineal Complications After Abdominoperineal Resection

Completed Last updated 1 February 2024

What this trial tests

trial testing Composite mesh in Rectal Cancer in 30 participants. Completed in 28 February 2022.

Timeline

3 April 2020

Primary endpoint
28 February 2021

28 February 2022

Quick facts

Lead sponsor	Elisa Mäkäräinen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	30
Start date	3 April 2020
Primary completion	28 February 2021
Estimated completion	28 February 2022
Sites	1 location across Finland

Drugs / interventions tested

Composite mesh

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Abdominoperineal Resection — all drugs for Abdominoperineal Resection →
Wound Heal — all drugs for Wound Heal →

Sponsor

Elisa Mäkäräinen

Who can join

18 and older, any sex, with Rectal Cancer or Abdominoperineal Resection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Abdominoperineal resection leaves an empty space to be filled by mesh or musculocutaneus flap. Several studies have reported over 30% morbidity with perineal wound healing after abdominoperineal resection. Preoperative radiotherapy is a strong predictor for perineal complications. Musculocutaneus flaps and use of biological mesh seem to minimize perineal morbidity. The role of omentoplasty at APR is controversial. Previous studies on synthetic mesh repair on perineum are almost lacking.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04334421 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Elisa Mäkäräinen
Last refreshed: 1 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04334421.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing